Related Experiment Videos
Somatostatin in neurodegenerative illnesses
1Neurochemistry Laboratory, Massachusetts General Hospital, Boston 02114.
Metabolism: Clinical and Experimental
|September 1, 1990
Summary
Somatostatin levels and neuron changes are altered in Alzheimer's, Parkinson's, and Huntington's diseases, suggesting a role in neurodegeneration. Further research is needed to understand these somatostatin alterations in disease.
Area of Science:
- Neuroscience
- Neuropathology
- Molecular Biology
Background:
- Somatostatin is a neuropeptide implicated in various physiological processes.
- Neurodegenerative diseases are characterized by progressive neuronal dysfunction and loss.
- Altered neuropeptide signaling is a potential factor in neurodegenerative conditions.
Purpose of the Study:
- To investigate the role of somatostatin in Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD).
- To examine somatostatin concentrations and neuronal morphology in the brains of patients with these neurodegenerative disorders.
Main Methods:
- Analysis of somatostatin concentrations in specific brain regions (cerebral cortex, basal ganglia).
- Assessment of somatostatin neuron density and morphology (dystrophy) in affected brain areas.
Main Results:
- Reduced somatostatin concentrations and dystrophic/reduced somatostatin neurons observed in the cerebral cortex in AD and PD dementia.
- Increased somatostatin concentrations and neuron density found in the basal ganglia in HD.
Conclusions:
- Somatostatin system alterations are evident across multiple neurodegenerative diseases, including AD, PD, and HD.
- The specific contribution of these somatostatin changes to the pathophysiology of these diseases remains to be elucidated.